State of Oklahoma **Oklahoma Health Care Authority** Folotyn[®] (Pralatrexate) Prior Authorization Form



Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Physician billing (HCPCS code	-	date of next dose):
Dose:	Regimen:	
	Billing Provider Inform	ation
Provider NPI: Provider Name:		lame:
Provider Phone:	Provider Fax:	·
	Prescriber Informati	ion
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
 2. Please indicate the diagnosis Adult T-Cell Leukemia Anaplastic Large Cell A. Does member have B. Will pralatrexate be Peripheral T-Cell Lym T-Cell Lymphoma, Ex A. Does member have combination cheme Primary Cutaneous Ly A. Will pralatrexate be 	ad as a single-agent? Yes No_ apsed or refractory disease? Yes and information: //Lymphoma Lymphoma (ALCL), Primary Cut e multifocal lesions or regional nod e used as primary treatment? Yes_ phoma (PTCL) tranodal NK/T-Cell Lymphoma, No e relapsed/refractory disease follow otherapy regimen not previously us (mphomas – Mycosis Fungoides e used as primary treatment? Yes_	taneous es? Yes No No No Ving additional therapy with an alternate sed? Yes No s (MF)/Sézary Syndrome (SS)
3. Has the member experienced	ence of progressive disease while of any adverse drug reactions relate erse reactions:	ed to pralatrexate therapy? Yes No
Drocoribor Signatura		Date:

knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization throughCoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.